DT

Deepak Thakral

Active Director Director DIN 05234307
DIN 05234307 First appointment Mar 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2012
Shareholding value •••• Premium profile

About Deepak Thakral

Data last updated:

Deepak Thakral is a Director at Lewis Bioserch Pharma Private Limited (since 2012). The company operates in Pharma. Lewis Bioserch Pharma Private Limited reported revenue of ₹4.94 Cr (FY 2024).

DIN 05234307
Primary Designation Director
Industry Pharma
First Appointment 22 Mar 2012
Oldest Company Age 14 yrs
Largest company Lewis Bioserch Pharma Private Limited · ₹4.94 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Mar 20122012₹4.94 Cr (FY 2024)Active

Board colleagues of Deepak Thakral

NameDINCompanyDesignation
Na Arti10041792Lewis Bioserch Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Lewis Bioserch Pharma Private Limited
Premium access

Shareholding and investment profile for Deepak Thakral

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Deepak Thakral

Deepak Thakral currently holds 1 directorship: Lewis Bioserch Pharma Private Limited (Director, since 22 Mar 2012, revenue ₹4.94 Cr (FY 2024)).

Deepak Thakral was first appointed on 22 Mar 2012 as Director at Lewis Bioserch Pharma Private Limited.

The current boards of Deepak Thakral's companies include Na Arti (Lewis Bioserch Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available